CT041 for Cancer of Pancreas

Locally Advanced
Recruiting · 18+ · All Sexes · Los Angeles, CA

This study is evaluating whether a type of white blood cell called a T-cell may help treat advanced stomach or pancreatic cancer.

See full description

About the trial for Cancer of Pancreas

Eligible Conditions
Pancreatic Neoplasms · Malignant Neoplasm of Stomach · Malignant Neoplasm of Pancreas

Treatment Groups

This trial involves 2 different treatments. CT041 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.


This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Voluntarily signed the ICF;
Age ≥ 18 and < 76 years with pathologically/histologically confirmed diagnosis of adenocarcinoma of the stomach or gastroesophageal junction, referred to collectively as STAD, or pancreatic adenocarcinoma (PAAD);
You have a tumor that is positive for CLDN18.2. show original
Failed or been intolerant of prior lines of systemic therapy;
Estimated life expectancy > 4 months;
At least 1 measurable lesion per RECIST 1.1;
You have no symptoms or signs of cancer. show original
Venous access is sufficient for leukapheresis collection. show original
Patients should have reasonable CBC counts, renal and hepatic functions;
Women of childbearing age must undergo a serum pregnancy test with negative results before screening and infusion and be willing to use effective and reliable method of contraception;
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: day 1 - month 18
Screening: ~3 weeks
Treatment: Varies
Reporting: day 1 - month 18
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: day 1 - month 18.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether CT041 will improve 2 primary outcomes and 6 secondary outcomes in patients with Cancer of Pancreas. Measurement will happen over the course of day 1 - month 18.

Progression free survival
DAY 1 - MONTH 18
duration time after CT041 treatment that patient lives without worsening of disease
DAY 1 - MONTH 18
Disease Control Rate
DAY 1 - MONTH 18
Percentage of patients response at least 90 days
DAY 1 - MONTH 18
Overall survival
DAY 1 - MONTH 18
duration time after CT041 treatment that patient lives
DAY 1 - MONTH 18
Time to Progression
DAY 1 - MONTH 18
Duration of time from CT041 treatment to progression of disease
DAY 1 - MONTH 18
Identification of Maximum Tolerated Dose (MTD)
DAY 1 - MONTH 18
Incidence of dose-limiting toxicities (DLTs)
DAY 1 - MONTH 18
Duration of Response
DAY 1 - MONTH 18
Duration of time from first response to progression of disease
DAY 1 - MONTH 18
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is cancer of pancreas?

In order to provide the best treatment to patients with [pancreatic cancer]( it is necessary to detect the cancer at the time of diagnosis. Therefore the symptoms and symptoms of pancreatic cancer are not sufficient enough to diagnose this cancer. The most common symptom of pancreatic cancer is a painful abdomen, due to rupture of the pancreas. There are other symptoms like nausea, headache, back pain, weight loss and loss of appetite.

Anonymous Patient Answer

How many people get cancer of pancreas a year in the United States?

Approximately 2.2 million new cases of [pancreas cancer]( are diagnosed each year in America, making this disease amongst the most common of all cancers in the US. It also accounts for 2% of all cancers diagnosed in people under the age of 50 and 8% of all male cancers diagnosed. There may be more deaths from pancreas cancer than breast cancer, prostate cancer, colorectal cancer, or lung cancer combined. The 5-year survival rate for patients who have surgically resected invasive adenocarcinoma is very high (69%) when compared with other cancers in this age group.

Anonymous Patient Answer

What are common treatments for cancer of pancreas?

The incidence of type two diabetes mellitus is increasing, so it is an ever-present risk factor for patients with pancreatic cancer. The incidence of advanced pancreatic cancer is also increasing, with the five-year survival rate dropping from 46% in 1997 to 37% in 2011. There is no cure for either type two or advanced pancreatic cancer, and pancreatic cancer presents with a high mortality rate. Treatment for pancreatic cancer depends on the staging of disease as reflected by TNM (tumor, lymph nodes, metastases) classification. Common treatments for pancreatic cancer included surgery, chemotherapy, radiation therapy, targeted therapy, and a combination of these.

Anonymous Patient Answer

Can cancer of pancreas be cured?

Can cancer of pancreas be cured? No. Although no cure was obtained for any patient, in the majority of patients, the tumour was controlled and symptoms improved.

Anonymous Patient Answer

What are the signs of cancer of pancreas?

The cancer of pancreas may have signs such as pancreatic enlargement, altered bowel habits, jaundice and weight loss. On biopsy, the cancer of pancreas may present as moderately differentiated or poorly differentiated carcinoma, with or without perineural invasion, peritumoral vascular invasion or nodular pattern. The cancer of pancreas may present as periampullary carcinoma.

Anonymous Patient Answer

What causes cancer of pancreas?

The etiology of [pancreatic cancer]( is multifactorial and the role of genetic susceptibility differs between the types of pancreatic cancer. Factors such as smoking, alcohol consumption, diabetes mellitus, and obesity do not appear to worsen cancer survival after adjustment for demographic risk factors.

Anonymous Patient Answer

What are the chances of developing cancer of pancreas?

The five year risk of developing PC is 4.5%. It can happen to anyone, but is 1% more common in women than men. The risk of developing PC increases as the person gets older. The risk of PC is around 1% for a person from ages 45 to 50, while in persons aged 80, the risk is around 4%. The 5 year risk of developing melanoma is 1.7%, while the risk for colon cancer is 8.5%. The 2 year risk of developing breast cancer in a woman is 1.8%. The risk of PC in men is 1.2%. The probability of developing prostate cancer increases in men with age. The five year risk is 10.

Anonymous Patient Answer

What is the latest research for cancer of pancreas?

At present, the most effective treatment for pancreatic cancer remains surgical resection combined with systemic therapy (the most commonly used treatment) with radiation therapy following pancreatic cancer surgery.

Anonymous Patient Answer

What is the survival rate for cancer of pancreas?

Data from a recent study shows a long-term survival rate for patients with pancreatic carcinoma. However, further studies with large numbers of patients are needed to make any definite conclusions.

Anonymous Patient Answer

What is the primary cause of cancer of pancreas?

Pancreatic cancer has the same three components of a cancer, namely 1) a neoplasm, 2) a metastasis, and 3) a precursor lesion. Cancer of pancreas is a [transition neoplasm from a precursor lesion to a neoplasm.

Anonymous Patient Answer

How serious can cancer of pancreas be?

Approximately 25% of patients with pancreatic carcinoma present with metastatic disease, often already at an advanced disease stage; an extraprocedural bleeding is the main cause of death. The median life expectancy after curative therapy is a decade.

Anonymous Patient Answer

What does ct041 usually treat?

Ct041 is the first oral compound developed to specifically target FUS-DDIT3B-PGN which is the cause of the majority of [pancreatic cancer]( cases, specifically pancreatic ductal adenocarcinomas and is one of the most fatal human cancers. Furthermore, Ct041 seems to be active at lower concentrations in pancreatic cancer cell lines than in normal cells suggesting better selectivity in pancreatic cancer cells compared to normal cells. For this study, we selected pancreatic cancer cell line MDA-PaCa as targets.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Cancer of Pancreas by sharing your contact details with the study coordinator.